You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: 6,133,251


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,133,251
Title: Combination compound for contraception based on natural estrogen
Abstract:The combination preparation for contraception includes a first stage of 2 to 4 first stage daily dosage portions, a second stage of two groups of second stage daily dosage portions, a third stage of 2 to 4 third stage daily dosage portions and an additional stage of 2 to 4 additional stage daily dosage portions. The first stage daily dosage portion is an effective amount of natural estrogen, the second stage daily dosage portion is an effective amount of a combination of natural estrogen and natural or synthetic gestogen, the third stage daily dosage portion is another effective amount of natural estrogen and an additional stage daily dosage portion consists of a placebo. The first group of the second stage consists of 3 to 5 daily dosage portions and the second group, 13 to 17 daily dosage portions. More of the gestogen is included in the effective amount in the second group of the second stage than in the first group. The effective amount of the natural estrogen is constant in both the first and third stages, but smaller in the third stage than in the first stage.
Inventor(s): Dittgen; Michael (Apolda, DE), Fricke; Sabine (Jena, DE), Hoffmann; Herbert (Jena, DE), Moore; Claudia (Jena, DE), Oettel; Michael (Jena, DE), Ostertag; Monika (Gottingen, DE)
Assignee: Jenapharm GmbH & Co. KG (Jena, DE)
Application Number:08/738,314
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 6,133,251

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,133,251

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany195 40 253Oct 28, 1995

International Family Members for US Patent 6,133,251

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0770388 ⤷  Sign Up CA 2009 00016 Denmark ⤷  Sign Up
European Patent Office 0770388 ⤷  Sign Up PA2009004 Lithuania ⤷  Sign Up
European Patent Office 0770388 ⤷  Sign Up PA2009004,C0770388 Lithuania ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.